Biogen Idec Inc. enrolled the first subject in its Phase III trial of injectable Adentri, which is being tested in a group that is considered particularly hard to treat: patients with worsening heart failure and poor kidney function. (BioWorld Today)

The flurry of merger and acquisition activity this year has been targeted mostly at U.S. companies, but their European brethren aren't being overlooked, now including London-based Protherics plc. (BioWorld Today)